Monday, March 30, 2020

Monday, March 30, 2020

Latest News

U.S. FOOD AND DRUG ADMINISTRATION: Public Workshop - Forum on Laser-Based Imaging - April 8, 2019

The Forum will focus on the latest trends and enhancements in laser-based imaging modalities such as Optical Coherence Tomography (OCT) and Adaptive Optics (AO), regulatory and reimbursement considerations, and new topics of interest such as the Medical Device Development Tool Program and the emerging role of Artificial Intelligence.


An audio podcast series featuring the Director of FDA Center for Drug Evaluation and Research


Drug shortages have a significant impact on both hospitals and patients.

U.S. FOOD AND DRUG ADMINISTRATION: The Breakthrough Therapy Designation

For two decades, CDER has used certain methods to speed drug development and the regulatory review process so that promising therapies can get to patients faster.

FDA issues safety alert regarding wearable defibrillator; two deaths attributed to software defect

Safety concerns have led to a government warning about a wearable defibrillator.

FDA issues warning of possible medical device shortage following shutdown of Sterigenics plant

FDA is warning of the possibility of a shortage of sterilized medical devices, possibly posing a threat to public health.

U.S. FOOD AND DRUG ADMINISTRATION: USDA and FDA Announce a Formal Agreement to Regulate Cell-Cultured Food Products from Cell Lines of Livestock and Poultry

The U.S. Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) and the U.S. Department of Health and Human Services’ (HHS) Food and Drug Administration (FDA) today announced a formal agreement to jointly oversee the production of human food products derived from the cells of livestock and poultry.

U.S. FOOD AND DRUG ADMINISTRATION: FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation

The U.S. Food and Drug Administration today approved a new indication for a heart valve repair device that is intended to reduce moderate-to-severe or severe mitral regurgitation, a leakage of blood backward through the mitral valve into the heart’s left atrium that can cause heart failure symptoms such as shortness of breath, fatigue and swelling in the legs.

U.S. FOOD AND DRUG ADMINISTRATION: FDA allows marketing of new device to help treat carbon monoxide poisoning

The U.S. Food and Drug Administration allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.

FDA finds 32,000 malfunctions, 366 deaths involving surgical staples over seven years

The Food and Drug Administration (FDA) is acknowledging a rise in medical device reports concerning surgical staples and staplers used internally.

Gottlieb weighs in on naming scheme for biological medicines for competition and patient safety

Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb released a statement last week on the importance of naming biological medicines that will benefit by having a lower cost to patients.

PHARMACEUTICS INTERNATIONAL, INC.: Pii to Manufacture FDA-approved Busulfan Injection Drug Product

Pharmaceutics International, Inc. (Pii), a Contract Development and Manufacturing Organization (CDMO) headquartered in Hunt Valley, Maryland, is pleased to announce the launch of Busulfan Injection, 6mg/mL in 10mL vials, in partnership with Athenex Pharmaceuticals, Sungen Pharma and Chemwerth.

ALLERGAN, PLC: Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.: Announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA.

VIOME: Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients

Viome, a company transforming health through personalized nutrition based on individual biology, today announces it will collaborate with precision health leader, Helomics, to study the link between the gut microbiome and ovarian cancer.

FDA Update: January-February medical device recalls

Recalls of medical devices occur when a company sees a need to either take corrective action or remove a potentially hazardous device from the market, according to the Food and Drug Administration.

NEUROTROPE INC.: Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease

Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today issued a statement on Biogen Inc.'s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer's disease.

FDA releases statement on new policies to curb youth access to flavored tobacco products

The Food and Drug Administration is looking toward a future where combustible cigarettes are not addictive and do not harm as many people as are currently affected by nicotine and additive chemicals.

ZIMMER BIOMET: Receives FDA Clearance of ROSA® ONE Spine System for Robotically-Assisted Surgeries

Zimmer Biomet becomes first company in the world with 510(k) clearance for Brain, Spine and Knee offerings on one robotic platform

FDA Health News